Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints
Notified -
Globe Newswire7-09-2025, 19:30
IdentiFlight Enters French Energy Market as e3 IDF GmbH Announces New Office in Nantes 18-12-2023, 16:00